As we get closer to the annual meeting of the American Society of Clinical Oncology (ASCO) — to be held at the beginning of June — the investor community is beginning its annual frenzy of speculation about exactly what new information will be presented at the meeting about development stage and marketed drugs. … READ MORE …
Filed under: Drugs in development | Tagged: abiraterone, ASCO, investment, MDV3100 | 1 Comment »
Search for new and
ongoing trials on the
CTAG PCa web site
